C-X-C motif chemokine ligand 12-C-X-C chemokine receptor type 4 signaling axis in cancer and the development of chemotherapeutic molecules

被引:2
作者
Yen, Jui-Hung [1 ]
Chang, Chun-Chun [2 ,3 ]
Hsu, Hao-Jen [4 ]
Yang, Chin-Hao [5 ]
Mani, Hemalatha [5 ]
Liou, Je-Wen [3 ,4 ,5 ]
机构
[1] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien, Taiwan
[2] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Lab Med, Hualien, Taiwan
[3] Tzu Chi Univ, Dept Lab Med & Biotechnol, Hualien, Taiwan
[4] Tzu Chi Univ, Dept Biomed Sci & Engn, Hualien, Taiwan
[5] Tzu Chi Univ, Sch Med, Dept Biochem, 701 Zhongyang Rd,Sect 3, Hualien, Taiwan
来源
TZU CHI MEDICAL JOURNAL | 2024年 / 36卷 / 03期
关键词
Cancer progression; Chemotherapeutic agents; CXCL12; CXCR4; Stromal cell-derived factor 1; LYMPH-NODE METASTASIS; G-BETA-GAMMA; NF-KAPPA-B; CXCR4; EXPRESSION; CELL-SURVIVAL; IMMUNE SURVEILLANCE; DOWN-REGULATION; BINDING-SITE; ACTIVATION; BREAST;
D O I
10.4103/tcmj.tcmj_52_24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chemokines are small, secreted cytokines crucial in the regulation of a variety of cell functions. The binding of chemokine C-X-C motif chemokine ligand 12 (CXCL12) (stromal cell-derived factor 1) to a G-protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) triggers downstream signaling pathways with effects on cell survival, proliferation, chemotaxis, migration, and gene expression. Intensive and extensive investigations have provided evidence suggesting that the CXCL12-CXCR4 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, as well as in creating tumor microenvironment, thus implying that this axis is a potential target for the development of cancer therapies. The structures of CXCL12 and CXCR4 have been resolved with experimental methods such as X-ray crystallography, NMR, or cryo-EM. Therefore, it is possible to apply structure-based computational approaches to discover, design, and modify therapeutic molecules for cancer treatments. Here, we summarize the current understanding of the roles played by the CXCL12-CXCR4 signaling axis in cellular functions linking to cancer progression and metastasis. This review also provides an introduction to protein structures of CXCL12 and CXCR4 and the application of computer simulation and analysis in understanding CXCR4 activation and antagonist binding. Furthermore, examples of strategies and current progress in CXCL12-CXCR4 axis-targeted development of therapeutic anticancer inhibitors are discussed.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 114 条
  • [1] Ahn JY, 2013, APPL IMMUNOHISTO M M, V21, P79, DOI 10.1097/PAI.0b013e3182606f4d
  • [2] The biology of CCR5 and CXCR4
    Alkhatib, Ghalib
    [J]. CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 96 - 103
  • [3] Phospholipase Cβ is critical for T cell chemotaxis
    Bach, Tami L.
    Chen, Qing-Min
    Kerr, Wesley T.
    Wang, Yanfeng
    Lian, Lurong
    Choi, John K.
    Wu, Dianqing
    Kazanietz, Marcelo G.
    Koretzky, Gary A.
    Zigmond, Sally
    Abrams, Charles S.
    [J]. JOURNAL OF IMMUNOLOGY, 2007, 179 (04) : 2223 - 2227
  • [4] CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
    Beider, Katia
    Begin, Michal
    Abraham, Michal
    Wald, Hanna
    Weiss, Ido D.
    Wald, Ori
    Pikarsky, Eli
    Zeira, Evelyne
    Eizenberg, Orly
    Galun, Eithan
    Hardan, Izhar
    Engelhard, Dan
    Nagler, Arnon
    Peled, Amnon
    [J]. EXPERIMENTAL HEMATOLOGY, 2011, 39 (03) : 282 - 292
  • [5] Decoys and Cardiovascular Development: CXCR7 and Regulation of Adrenomedullin Signaling
    Betterman, Kelly L.
    Harvey, Natasha L.
    [J]. DEVELOPMENTAL CELL, 2014, 30 (05) : 490 - 491
  • [6] BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
    Bockorny, Bruno
    Semenisty, Valerya
    Macarulla, Teresa
    Borazanci, Erkut
    Wolpin, Brian M.
    Stemmer, Salomon M.
    Golan, Talia
    Geva, Ravit
    Borad, Mitesh J.
    Pedersen, Katrina S.
    Park, Joon Oh
    Ramirez, Robert A.
    Abad, David G.
    Feliu, Jaime
    Munoz, Andres
    Ponz-Sarvise, Mariano
    Peled, Amnon
    Lustig, Tzipora M.
    Bohana-Kashtan, Osnat
    Shaw, Stephen M.
    Sorani, Ella
    Chaney, Marya
    Kadosh, Shaul
    Haras, Abi Vainstein
    Von Hoff, Daniel D.
    Hidalgo, Manuel
    [J]. NATURE MEDICINE, 2020, 26 (06) : 878 - +
  • [7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [8] Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
    Brock, C
    Schaefer, M
    Reusch, HP
    Czupalla, C
    Michalke, M
    Spicher, K
    Schultz, G
    Nürnberg, B
    [J]. JOURNAL OF CELL BIOLOGY, 2003, 160 (01) : 89 - 99
  • [9] cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: Effects of PKA and EPAC
    Burdyga, Alex
    Conant, Alan
    Haynes, Lee
    Zhang, Jin
    Jalink, Kees
    Sutton, Robert
    Neoptolernos, John
    Costello, Eithne
    Tepikin, Alexei
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2013, 1833 (12): : 2664 - 2672
  • [10] Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
    Burger, M
    Hartmann, T
    Krome, M
    Rawluk, J
    Tamamura, H
    Fujii, N
    Kipps, TJ
    Burger, JA
    [J]. BLOOD, 2005, 106 (05) : 1824 - 1830